文献速递自身免疫性与大疱性皮肤病

循环活化自身反应性Dsg3特异性滤泡调节性T细胞出现与利妥昔单抗治疗寻常型天疱疮长期疗效相关

The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.
PubMed 文献 · Br J Dermatol · 2024-01-01

本研究利用HLA-DRB1*0402四聚体负载Dsg3免疫优势肽,通过流式细胞术分析寻常型天疱疮患者基线、第6个月及长期随访(第60-90个月)外周血Dsg3特异性滤泡T细胞亚群。结果显示利妥昔单抗治疗诱导自身反应性Tfh减少,并出现高表达PD1、ICOS和CD25的Dsg3特异性Tfr亚群,而单用糖皮质激素患者中极少见。提示Dsg3特异性Tfr的出现与利妥昔单抗长期疗效相关。

要点

  • 利妥昔单抗治疗可减少寻常型天疱疮患者自身反应性Dsg3特异性Tfh细胞。
  • 利妥昔单抗治疗后出现活化的Dsg3特异性Tfr细胞,高表达PD1、ICOS和CD25。
  • 单用糖皮质激素患者中Dsg3特异性Tfr细胞极少见。

核心结论

  • 循环自身反应性Dsg3特异性Tfr细胞的出现与利妥昔单抗治疗寻常型天疱疮的长期疗效相关。

研究设计与样本

  • 利用HLA-DRB1*0402四聚体负载Dsg3免疫优势肽,流式细胞术分析寻常型天疱疮患者外周血Dsg3特异性滤泡T细胞。
  • 分析时间点为基线、第6个月和长期随访(第60-90个月)。

主要发现

  • 基线时自身反应性Dsg3特异性Tfh细胞中Tfh1*和Tfh17亚群占优势,Tfh2亚群减少。
  • 利妥昔单抗治疗诱导自身反应性Tfh细胞减少,随访期间对其极化无影响。
  • 出现Dsg3特异性Tfr亚群,显著高表达表面活化标志物PD1、ICOS和CD25。
  • 单用糖皮质激素治疗的寻常型天疱疮患者中Dsg3特异性Tfr细胞极少见。

临床怎么用

  • 利妥昔单抗治疗寻常型天疱疮后监测Dsg3特异性Tfr细胞可能有助于评估长期缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pemphigus vulgaris (PV) is characterized by autoantibodies targeting keratinocyte adhesion proteins desmoglein (Dsg) 1 and 3, and by the human leukocyte antigen (HLA) predisposition allele HLA-DRB1*0402. Treatment using rituximab (RTX) combined with short-term corticosteroids (CS) allows disease control and long-lasting remission. OBJECTIVES: The principal aim of this study was to evaluate the impact of RTX on the circulating subpopulations of Dsg3-specific T lymphocytes that specifically regulate B-cell responses: follicular helper T (Tfh) and follicular regulatory T (Tfr) lymphocytes. METHODS: Using the HLA-DRB1*0402 tetramer loaded with the Dsg3 immunodominant peptide, we used flow cytometry to analyse the frequency, polarization and activation status of blood Dsg3-specific follicular T-cell populations at baseline, month (M) 6 and long-term follow-up (M60-90) from patients with PV. RESULTS: At baseline, we observed a predominance of Tfh1* and Tfh17 subsets and an underrepresentation of the Tfh2 subset among autoreactive Dsg3-specific Tfh cells compared with nonautoreactive Tfh cells. RTX treatment induced a decrease of autoreactive Tfh cells with no effect on their polarization during follow-up. In parallel, we observed the emergence of a Dsg3-specific Tfr subpopulation with a significant overexpression of the surface activation markers PD1, ICOS and CD25 that was not observed at the surface of autoreactive Tfh and nonautoreactive Tfr cells of the same patients with PV. In contrast, very few Dsg3-specific Tfr cells were observed in patients with PV who were treated with CS alone. CONCLUSIONS: Here we show that the emergence of circulating autoreactive Dsg3-specific Tfr cells is associated with the long-term efficacy of RTX in patients with PV. Pemphigus vulgaris (PV) is an autoimmune disease mediated by pathogenic antibodies directed against the body’s own tissues (called autoantibodies). In this condition, autoantibodies bind to and inhibit a protein called desmoglein 3 (Dsg3), which is responsible for the adhesion of keratinocytes (cells that make up the superficial layers of the skin and mucous membranes). As a result, PV causes painful blistering. People with PV are commonly treated with low doses of oral corticosteroids (prednisone) and rituximab (administered via infusions), which have significantly improved patient outcomes. Rituximab temporarily (for 6–9 months) depletes B lymphocytes, which are immune cells that differentiate into cells producing anti-Dsg3 antibodies. While autoimmune diseases can be lifelong, this study looked at why some people achieve long-lasting remissions without ongoing treatment, even after the return of B lymphocytes. We analysed anti-Dsg3 follicular T cells, which regulate B-cell differentiation. Among these, we observed the emergence of regulatory (or inhibiting) T cells over time following treatment, accompanied by a decrease in conventional (or activating) follicular T cells. We also found that these autoimmune follicular regulatory T cells were more activated compared with conventional follicular T cells or other T cells not directed against the Dsg3 protein. Overall, our findings suggest that the emergence of these follicular regulatory T cells may be responsible for the sustained remission observed in some people with PV and could be promoted by the use of rituximab.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hébert V, Novarino J, Maho-Vaillant M, et al. The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris. Br J Dermatol. 2024. PMID: 38848544. doi:10.1093/bjd/ljae220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。